US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

US IPOs and Secondary Offerings

Scribe Therapeutics Inc. (SCTX): CRISPR Biotech Attracts Blue-Chip Support, Demand Strong for IPO

Scribe Therapeutics (SCTX): Strong Hands, Strong Start: Scribe Therapeutics Impresses on Debut

Scribe Therapeutics Inc. (SCTX): Peeking at the IPO Prospectus of a Biotech Using CRISPR Technology

IPOs and Secondary Offerings

Equity Capital Markets

Scribe Therapeutics / Equity Capital Markets

<ul>
<li>Scribe Therapeutics is set to revive biotech IPO activity with a CRISPR-focused offering backed by strategic investors Eli Lilly and Sanofi.</li>
<li>The clinical-stage biotech’s lead candidate, STX-1150, remains early with Phase 1 data expected in 1H27, requiring investor patience.</li>
<li>Scribe’s CRISPR platform targets large cardiovascular markets, supported by blue-chip partnerships and prominent venture investors including Andreessen Horowitz.</li>
</ul>


Scribe Therapeutics is set to revive biotech IPO activity with a CRISPR-focused offering backed by strategic investors Eli Lilly and Sanofi.
The clinical-stage biotech’s lead candidate, STX-1150, remains early with Phase 1 data expected in 1H27, requiring investor patience.
Scribe’s CRISPR platform targets large cardiovascular markets, supported by blue-chip partnerships and prominent venture investors including Andreessen Horowitz.


Scribe Therapeutics Inc. (SCTX): Small Cap CRISPR Biotech Sets Terms Seeking $100m Raise